Has There Been A Sea Change In Trial Diversity Efforts?
Executive Summary
PhRMA partnered with Deloitte to produce a report that included a survey of 31 member companies indicating that most had made significant investments in improving clinical trial diversity.
You may also be interested in...
Novartis Looks To Take Its Diversity Show On The Road
Head of clinical trial diversity and inclusion Kim Fookes spoke with Scrip about Novartis’s US trial diversity initiatives and early plans to expand them abroad.
How BMS Is Tackling Clinical Trial Diversity
The company’s director of clinical trial diversity strategy, Lorena Kuri, talked to Scrip about how she became interested in trial diversity and what BMS is doing to increase it.
Clinical Trial Diversity Efforts Look Beyond COVID-19
At The Atlantic’s Health Equity Summit, panel discussions highlighted efforts to improve diversity in clinical trials of diseases like lupus, which disproportionately affects women of color.